Who are we and what do we do?

As a global biopharmaceutical company, our activities touch many people’s lives. We work closely with all our stakeholders to understand their challenges and how we can combine our skills and resources to achieve a common goal: improved health.

Learn more

AZ Health Connections

  • Science of Novel Drug Delivery in Respiratory Medicine 26 April 2016 13:40 BST

    AstraZeneca’s latest approval BEVESPI AEROSPHERE™ (glycopyrrolate and formoterol fumarate) inhalation aerosol, is the first long-acting muscarinic antagonist (LAMA), and formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA) delivered in a pressurized metered dose inhaler (pMDI).